A new wave of medications for diabetes and weight loss has been hailed for its health benefits, but recent research delivers a sobering warning: stopping them could erase their protective effects and significantly raise the risk of heart attack and stroke.
The Rise of 'Miracle' Drugs
A class of drugs known as GLP-1 receptor agonists has transformed the treatment landscape for type 2 diabetes and, more recently, obesity. Medications like semaglutide (found in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) work by mimicking a gut hormone that helps regulate blood sugar, reduce appetite, and promote a feeling of fullness. Beyond managing blood sugar and inducing weight loss, these drugs have been celebrated for their significant cardiovascular benefits, including lowering the risk of heart attacks and strokes. This has made them a cornerstone of modern treatment, with their popularity surging across India and the globe.
A Sobering New Finding
The headline-making benefits, however, appear to be conditional on continuous use. A recent study published in The Lancet Regional Health Europe found that people with type 2 diabetes who stopped taking their GLP-1 medication had nearly double the risk of suffering a heart attack, stroke, or dying compared to those who continued the treatment. Specifically, the study observed roughly four major adverse cardiovascular events per 100 people per year among those who discontinued the drug, compared to just two events in the group that stayed on it. Another major study published in BMJ Medicine echoed these concerns, finding that stopping the drugs for two years was linked to a 22% increased risk of major cardiovascular events. This suggests the heart-protective shield these drugs provide is not permanent and can vanish surprisingly quickly.
Why Does Stopping Increase Risk?
The protection offered by GLP-1 drugs is an active process. They help improve several cardiometabolic risk factors, such as blood pressure, cholesterol levels, and inflammation. When a patient stops taking the medication, these benefits begin to reverse. Senior author of the BMJ Medicine study, Dr. Ziyad Al-Aly, described this phenomenon as a 'metabolic whiplash'. While visible weight regain is a well-known consequence of stopping these drugs, the invisible reversal of metabolic improvements is what appears to be detrimental to heart health. Appetite returns, blood sugar levels can spike, and the positive effects on blood vessels and inflammation fade, leaving the patient once again vulnerable to cardiovascular events.
The Importance of Continuous Use
The research highlights a graded relationship: the longer you are off the medication, the more the protective benefits diminish. The BMJ Medicine study noted that even a sixndelay interruption was associated with an increased risk. After one year of discontinuation, the risk of cardiovascular events was 14% higher than for continuous users, climbing to 22% after two years. This effectively wipes out the cardiovascular protection gained while on the therapy. The findings underscore that these are not shortndterm cures but longterm management tools. Unfortunately, high discontinuation rates are common, often due to side effects, cost, or supply shortages, with some studies showing nearly 6 in 10 US adults stop within a year.
What Should Patients Do?
The key takeaway from this research is not that the drugs are dangerous, but that their benefits are tied to consistent use. Experts stress that patients should not stop these medications abruptly or without consulting their doctor. If you are taking a GLP -1 medication for diabetes or weight management and considering stopping, it is crucial to have a conversation with your healthcare provider. They can help you understand the risks and benefits, manage any side effects, and create a comprehensive health plan. This might involve tapering off the dose, transitioning to an alternative therapy, or doubling down on lifestyle changes to help maintain the health gains you’ve achieved.
